NDA 213464 · Bayer Healthcare
Lampit
Nifurtimox · Oral
NovelAccelerated approvalPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Jun 2, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Aug 6, 2020
Approved uses
2
Original approval plus efficacy supplements
Registered trials
15
6 Phase 3, 0 recruiting
FAERS reports
26
21 serious, 3 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 3, 2026.
LAMPIT is indicated in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis) caused by Trypanosoma cruzi [see Clinical Studies ( 14 )]. LAMPIT is a nitrofuran antiprotozoal, indicated in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis), caused by Trypanosoma cruzi . ( 1 )
Mechanism: Nifurtimox is an antiprotozoal drug [see Microbiology ( 12.4 )] . Mechanism of Action The mechanism of action of nifurtimox is not fully understood. Studies suggest that nifurtimox is metabolized/activated, by Type I (oxygen insensitive) and Type II (oxygen sensitive) nitoreductases (NTR) leading to production of toxic intermediate metabolites and/or reactive oxygen species that induce DNA damage and cell death of both intracellular and extracellular forms of T. cruzi .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 2, 2023 Supplement 5 · Efficacy OrphanLetterLabel
- Aug 6, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelLetterReview
2 products under this application
- LAMPIT · NIFURTIMOX 120MG · TABLET, ORAL · Prescription
- LAMPIT · NIFURTIMOX 30MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Nifurtimox" as an intervention, any sponsor and status, largest first.
Drugs for Neglected DiseasesAcademic, hospital or other
NCT00906880 · 630 participants · Start Apr 2009 · Primary completion Sep 2010
Drug: Nifurtimox-Eflronithine Combination Treatment (NECT) · For: Human African Trypanosomiasis
Sites: Bandundu, Republic of the Congo; Kwamouth, Republic of the Congo; Yasa Bonga, Republic of the Congo · 6 sites in all
- CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY)Pivotal-lookingStatus unknown
Universidad Autónoma de BucaramangaAcademic, hospital or other
NCT02369978 · 500 participants (planned) · Start Aug 2015 · Primary completion Aug 2018
Drug: Nifurtimox; Benznidazole and 1 more · For: Chagas Disease
Sites: Bucaramanga, Colombia
- New Therapies and Biomarkers for Chagas InfectionPivotal-lookingCompleted
University of Texas, El PasoAcademic, hospital or other
NCT03981523 · 450 participants · Start Dec 18, 2019 · Primary completion May 29, 2024
Drug: Benznidazole; Nifurtimox · For: Trypanosoma Cruzi Infection; Chagas Disease
Sites: Cochabamba, Bolivia; Tarija, Bolivia; Sucre, Bolivia
- Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African TrypanosomiasisPivotal-lookingTerminated
EpicentreAcademic, hospital or other
NCT00330148 · 435 participants · Start Mar 2001
Drug: melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d; melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d and 1 more · For: Trypanosomiasis, African
Sites: Omugo, Uganda
- Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2Pivotal-lookingCompleted
Drugs for Neglected DiseasesAcademic, hospital or other
NCT01685827 · 394 participants · Start Oct 2012 · Primary completion Nov 11, 2016
Drug: Fexinidazole; Nifurtimox and 1 more · For: Human African Trypanosomiasis (HAT); Sleeping Sickness
Sites: Batangafo, Central African Republic; Bagata, Democratic Republic of the Congo; Masi Manimba, Republic of the Congo · 10 sites in all
- A Study to Learn How Well Nifurtimox Works and How Safe it is in Children Aged 0 to 17 Years With Chagas' Disease, an Inflammatory, Infectious Disease Caused by the Parasite Trypanosoma CruziPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT02625974 · 330 participants · Start Jan 27, 2016 · Primary completion Jul 25, 2018
Drug: Nifurtimox (Lampit, BAYA2502); Placebo · For: Chagas Disease
Sites: La Plata, Argentina; Buenos Aires, Argentina; San Salvador de Jujuy, Argentina · 25 sites in all
- Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African TrypanosomiasisPivotal-lookingCompleted
Drugs for Neglected DiseasesAcademic, hospital or other
NCT00146627 · 280 participants (planned) · Primary completion Jun 2008
Drug: Eflornithine; Nifurtimox · For: Trypanosomiasis, African
Sites: Isangi, Democratic Republic of the Congo; Katanda, Democratic Republic of the Congo; Mbuyi Maji, Democratic Republic of the Congo · 4 sites in all
Giselle ShollerAcademic, hospital or other
NCT00601003 · 112 participants · Start Jan 14, 2008 · Primary completion Apr 28, 2020
Drug: Nifurtimox; Cyclophosphamide and 1 more · For: Neuroblastoma; Medulloblastoma
Sites: San Diego, California; Hartford, Connecticut; Orlando, Florida · 15 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea9
- asthenia7
- dysmetria6
- vision blurred6
- headache4
- diarrhoea3
- pyrexia3
- vomiting3
- abdominal pain2
- drug rash with eosinophilia and systemic symptoms2
- dyspnoea2
- eosinophilia2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 3 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2018 | 4 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 5 |
| 2022 | 2 |
| 2023 | 2 |
| 2026 | 2 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Early assessment of antibodies decline in Chagas patients following treatment using a serological multiplex immunoassay.
Saade U, de Boer J, Scandale I, et al. · Nat Commun 2024 · Randomized Controlled Trial, Clinical Trial, Phase II
- Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection).
Vallejo M, Reyes PP, Martinez Garcia M, et al. · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Chemotherapy for second-stage human African trypanosomiasis: drugs in use.
Lutje V, Probyn K, Seixas J, et al. · Cochrane Database Syst Rev 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Chemotherapy for second-stage human African trypanosomiasis.
Lutje V, Seixas J, Kennedy A · Cochrane Database Syst Rev 2013 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Chemotherapy for second-stage Human African trypanosomiasis.
Lutje V, Seixas J, Kennedy A · Cochrane Database Syst Rev 2010 · Meta-Analysis, Systematic Review
- Effectiveness of Nifurtimox Eflornithine Combination Therapy (NECT) in T. b. gambiense second stage sleeping sickness patients in the Democratic Republic of Congo: Report from a field study.
Kuemmerle A, Schmid C, Bernhard S, et al. · PLoS Negl Trop Dis 2021 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Bayer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.